Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about MERCK AND COMPANY
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/15BERGENBIO ASA : - Results for the Fourth Quarter and Full Year 2017
AQ
02/15MERCK AND : Announces Discontinuation of APECS Study Evaluating Verubecestat for..
AQ
02/15MERCK AND : Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neur..
BU
02/15BMS, Nektar partner on NKTR-214 combos in $3.6B deal
AQ
02/15ASTRAZENECA : Selumetinib in NF1 gets FDA orphan drug status
AQ
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14MERCK AND : halts Phase III trial of AD candidate
AQ
02/14MERCK AND : Ends Clinical Trial of Alzheimer's Drug
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/13BERGENBIO ASA : Results for the Fourth Quarter and Full Year 2017
AQ
02/08MERCK AND : - First-of-its-Kind Study Reveals Concern about the Future of the Ve..
AQ
More most relevant news
All news about MERCK AND COMPANY
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
AQ
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/17MERCK AND : `Really Durable Benefit` Emerging With Bladder Cancer ImmunoTx
AQ
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
AQ
02/16MERCK AND : Pharma Group MSD (Merck) Announces Plans For New Biotech Facility In..
AQ
02/15BERGENBIO ASA : - Results for the Fourth Quarter and Full Year 2017
AQ
02/15MERCK AND : Announces Discontinuation of APECS Study Evaluating Verubecestat for..
AQ
More news
Sector news : Pharmaceuticals - NEC
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/19BASF to face millions in extra costs in UK each year from Brexit - Handelsbla..
RE
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19NOVARTIS : Correction to Novartis CEO story
DJ
02/19Stronger European Earnings Augur More M&A, Higher Dividends
DJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Biotech Forum Daily Digest For February 20th 
02/20COMPUGEN LTD. : An Undervalued Disruptive Innovation Company 
02/20WALL STREET BREAKFAST : Albertsons Scoops Up Rest Of Rite Aid 
02/20AGENUS : Positioned To Rapidly Enhance Shareholder Value 
02/19AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In 
Latest Tweets
12:15aWestminster's Robert Davis, the property developer and the Cube
2
12:05aWestminster's Robert Davis, the property developer and the Cube
3
02/20Westminster's Robert Davis, the property developer and the Cube
1
02/20Federal Court Overturns Gilead Sciences and Merck Patent Dispute  
02/20Cow bells and dinner at The Ivy - a full list of Westminster councillor Rober..
4
More tweets
Qtime:416
Financials ($)
Sales 2018 41 616 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,41%
P/E ratio 2018 17,33
P/E ratio 2019 13,94
EV / Sales 2018 4,02x
EV / Sales 2019 3,86x
Capitalization 153 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,7 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-0.50%153 359
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
AMGEN3.23%133 241